Dr Kluge's clinical research and development experience in radiochemistry, molecular imaging and clinical development is valued by the Board. He brings a critical mind to the requirements of clinical development of novel radionuclide-based products and devices to enable clinical trials and commercialisation. He is a registered physician and the author of patents and publications in the field of nuclear medicine, neurology, infection and immunology. Dr Kluge is a Founder, General Manager and Medical Director of ABX CRO Advanced Pharmaceutical Services GmbH (since August 2002), a full service Contract Research Organisation (CRO) for Phase I-III biological, radiopharmaceutical and anticancer trials based in Dresden, Germany. He was also a Founder and founding CEO of ABX GmbH (www.abx.de) (from September 1996 to July 2002), one of the manufacturers of radiopharmaceutical precursors globally.
